Serotonergic psychotropic medications, including many antidepressants, have long been
known to trigger the condition. The US FDA 1 has now reported the condition in a number of …

The serotonin syndrome is an acute adverse reaction to medications that enhance
serotonergic activity. The severity of cases ranges from mild to fatal. Recently, the US Food …

(Headache 2010; 50: 1089‐1099) Background.—In 2006, a US Food and Drug
Administration (FDA) alert warned about the potential life‐threatening risk of serotonin …

Importance In 2006, the US Food and Drug Administration (FDA) issued an advisory
warning on the risk of serotonin syndrome with concomitant use of triptans and selective …

In July 2006, the FDA issued an alert regarding a “poten-tially life-threatening” interaction
between triptans (the most effective abortive medications for migraine) and selective …

2. US Food and Drug Administration. Information for healthcare professionals. Selective
serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors …

Objective.—To discern the prevalence of concomitant use of a triptan and a selective
serotonin reuptake inhibitor (SSRI) or a selective serotonin/norepinephrine reuptake …

Dear Sir I read the article,'Serotonin syndrome and rhabdomyolysis induced by concomitant
use of triptans, fluoxetine and hypericum'by Bonetto et al. with concern (1). Their conclusion …

Objective.—The present study was designed to discern the prevalence of concomitant use of
a 5‐hydroxytryptamine receptor agonist (triptan), and a selective serotonin reuptake inhibitor …

Background Little information exists about the actual prescription of triptans within large,
geographically diverse populations, in terms of demographic characteristics and co …